

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Art Unit: 1644
)	Examiner: ROONEY, Nora
Stephan R. TARGAN, et al.)	
)	
Application No: 10/723,164)	
)	
Filed: November 26, 2003)	
)	
For: <i>METHODS OF ASSESSING CROHN'S</i>)	
<i>DISEASE PATIENT PHENOTYPE BY I2, OMPC,</i>)	
<u><i>AND ASCA SEROLOGIC RESPONSE</i></u>)	

DECLARATION OF STEPHAN R. TARGAN PURSUANT TO 37 CFR 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I, Stephan R. Targan, declare and state as follows:

1. Cedars-Sinai Medical Center is the assignee of the entire right, title and interest of the above-referenced patent application.
2. I am one of the inventors named in the above-referenced patent application and am familiar with the claims of that patent application as they are presently pending.
3. I am a co-author of the journal publication by Targan, S., Landers, C., Steinhart, H., Feagan, B., and Greenberg, G., "Crohn's Disease (CD): Preliminary Evidence for the Association of High Level Serum Antibodies to Bacteria Associated Antigens with Antibiotic Induced Clinical Remission," *Gastroenterology*, Volume 122, No. 4, Supplement, page A-177, number S1176 (the "Targan, *et al.* Reference"). Drs. Landers, Steinhart, Feagan, and Greenberg are co-authors of the Targan, *et al.* Reference, but are

not co-inventors of the subject matter of the instant application.

4. The work described in the Targan, *et al.* Reference is my own work. To the extent that any subject matter disclosed in the Targan *et al.* Reference is described and/or claimed in the above-referenced patent application, the work relates only to my inventive contribution to the invention and not to the contributions of my co-inventors.
5. I hereby declare that all statements made of my own knowledge are true and that all statements made on information and belief are believed to be true, and, further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application and any patent issued thereon.


Stephan R. Targan

7-2-07
Date